| Trial Name | Description |
| Stellar-311 NE |
Dr. E. Tsvetkova Not yet open - A Phase 2/3, multicenter, randomized open-label study of zanzalintinib vs everolimus in participants with previously treated, unresectable, locally advanced or metastatic neuroendocrine tumors |